AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02293018
Drug: 0.75% (w/w) MTC896 Gel Once Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02293018
Drug: 0.75% (w/w) MTC896 Gel Twice Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02293018
Drug: 1.5% (w/w) MTC896 Gel Once Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04380961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo IV single dose infusion on Day 1.
Trial: NCT00914602
Drug: Sinemet 25-100 Oral Tablet
RxNorm normalized name: Sinemet 25-100 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
Trial: NCT01724983
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00738842
Drug: AZD6140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets taken bid for 5 days
Trial: NCT00738842
Drug: Placebo to match AZD6140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets taken bid for 5 days
Trial: NCT03070522
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02599792
Drug: Placebo for CTP-656
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00740545
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women inject ourselves every days with placebo
Trial: NCT03859323
Drug: SHP681
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC injection of SHP681 in the abdomen.
Trial: NCT02094872
Drug: MEK 162 therapy or molecularly targeted therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: molecularly targeted therapy, MEK 162 therapy
Trial: NCT02194049
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00051558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo, daily, 36 months
Trial: NCT00051558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection placebo, daily, 36 months
Trial: NCT03779035
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250mg/m2
Trial: NCT03785496
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
Trial: NCT02364947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed; tablets, orally
Trial: NCT02536170
Drug: L-arginine Loading Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
Trial: NCT03230162
Drug: low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
Trial: NCT00509496
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day x 2 days intravenous
Trial: NCT02042729
Drug: E2022- Current Formula Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.
Trial: NCT02042729
Drug: E2022- New Formula Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.
Trial: NCT02042729
Drug: E2022 Matching Placebo- Current Formula Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02042729
Drug: E2022 Matching Placebo- New Formula Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02583802
Drug: Ear pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
Trial: NCT02583802
Drug: Shengmai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
Trial: NCT02607254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
Trial: NCT04000451
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
Trial: NCT02681055
Drug: MN-001
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
Trial: NCT00127530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill, twice a day (b.i.d.)
Trial: NCT04044209
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
Trial: NCT00831441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, twice daily, until study end
Trial: NCT03956017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
Trial: NCT03975283
Drug: Exparel 266 MG Per 20 ML Injection
RxNorm normalized name: Exparel 266 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
Trial: NCT00724282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth daily at bedtime for 9 days
Trial: NCT00960934
Drug: MK-5442
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
Trial: NCT00960934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched oral placebo to MK-5442
Trial: NCT00442013
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
Trial: NCT01030458
Drug: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
Trial: NCT00503360
Drug: SAD448
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00414700
Drug: ChondroCelect implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm².
Trial: NCT03959865
Drug: Long-acting GLP-1RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
Trial: NCT03959865
Drug: Short-acting GLP-1RA
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
Trial: NCT03959865
Drug: Exendin-based GLP-1RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
Trial: NCT03959865
Drug: Fixed ratio BI/GLP-1RA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
Trial: NCT03959865
Drug: Flexible BI/GLP-1RA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
Trial: NCT00071487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Trial: NCT02099838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
Trial: NCT03049046
Drug: CC100
RxNorm normalized name: CENTRAL LINE DRESSING KIT M#BSIPICC1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic caffeic acid phenethylester
Trial: NCT03049046
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent
Trial: NCT00370162
Drug: lactoserum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01369342
Drug: Group 1: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=intravenous use, in a single dose.
Trial: NCT04586114
Drug: Corticosteroids and Derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any systemic corticosteroid treatment administrated during ICU stay
Trial: NCT00620477
Drug: injection in the knee joint with 20 ml of chirocaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection in the knee joint with 20 ml of chirocaine 0.125%
Trial: NCT00620477
Drug: injection in the knee joint with 20 ml of physiological fluid
RxNorm normalized name: BOS TAURUS KNEE JOINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection in the knee joint with 20 ml of physiological fluid
Trial: NCT01840423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01840423
Drug: levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: entacapone + levodopa/carbidopa
Trial: NCT01479920
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Trial: NCT01056224
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
Trial: NCT04093518
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks
Trial: NCT04093518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks
Trial: NCT02529293
Drug: BioChaperone Lispro U-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of BioChaperone Lispro U-100
Trial: NCT02529293
Drug: BioChaperone Lispro U-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of BioChaperone Lispro U-200
Trial: NCT01782989
Drug: ORACEA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORACEA® (40mg doxycycline) capsule daily for 24 months
Trial: NCT01782989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for 24 months
Trial: NCT04112147
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 12-week of 100mg BID Antroquinonol placebo
Trial: NCT00324623
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00283504
Drug: ANTI-IGE THERAPY (XOLAIR)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
Trial: NCT04459702
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with the drug azithromycin
Trial: NCT01944046
Drug: Double blind phase Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
Trial: NCT03848221
Drug: Sensitive Eyes Rewetting Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitive Eyes Rewetting Drops is a rewetting drop.
Trial: NCT00904540
Drug: Lidoderm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
Trial: NCT04276545
Drug: IV administration of DEX to investigate the effects for functional nasal endoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
Trial: NCT02264795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Solution
Trial: NCT00399477
Drug: Rasagiline mesylate with Levodopa
RxNorm normalized name: Rasagiline Mesylate
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azilect®, Levodopa
Trial: NCT02007577
Drug: salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
Trial: NCT02007577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 3 tablets with breakfast and 4 tablets with dinner
Trial: NCT01552044
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg tablet once a day for 1 month
Trial: NCT01552044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet once a day for 1 month
Trial: NCT02504294
Drug: IV Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
Trial: NCT04351438
Drug: Active comparator: Filter TPE with citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received citrate-based anticoagulation with filter TPE
Trial: NCT02532218
Drug: ARI-3037MO
RxNorm normalized name: OVIS ARIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid lowering treatment Statins
Trial: NCT00366626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 7 days matched to Naltrexone
Trial: NCT00986999
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
Trial: NCT02255175
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive transdermal estradiol (100μg/day) for 3 weeks
Trial: NCT03998826
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg piroxicam
Trial: NCT03998826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00935025
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple oral doses, extended-release capsule
Trial: NCT00935025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple oral doses, capsule
Trial: NCT00421499
Drug: dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02709954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Trial: NCT02709954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
Trial: NCT02709954
Drug: Active Oral Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Trial: NCT02542748
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norepinephrine injection
Trial: NCT02268838
Drug: E6007 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01881308
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01881308
Drug: Co-medication: Synthetic DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
Trial: NCT03650881
Drug: Neutrogena ® Light Therapy Acne Mask (MASK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
Trial: NCT02427529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00951600
Drug: oxcarbazepine 300 mg/5mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01892748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
Trial: NCT00550225
Drug: GSK961081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
Trial: NCT00550225
Drug: GSK961081 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
Trial: NCT02101892
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os, daily, evening
Trial: NCT00388414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill once daily
Trial: NCT01156701
Drug: Receiving a prescription of Relenza for prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving a prescription of Relenza for prophylaxis
Trial: NCT00288158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no